This site is intended for Healthcare professionals only.

U.S. drug developer Capricor places Duchenne drug trial on hold


U.S. drug developer Capricor places Duchenne drug trial on hold

The trial, named “HOPE-2”, was testing the company’s lead experimental drug CAP-1002, according to California-based Capricor’s website.

New Delhi: Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy(DMD), a muscle-wasting disorder, citing a safety review.

The review follows a severe allergic reaction during infusion of the drug, the company said in a filing. The patient responded well to medical treatment and is currently asymptomatic.

The company has notified the U.S. Food and Drug Administration and is working with the agency on a mitigation plan, it said.

The trial, named “HOPE-2”, was testing the company’s lead experimental drug CAP-1002, according to California-based Capricor’s website.

DMD is a rare, genetic disorder that hampers muscle movement, mainly in men, affecting one in every 3,500 to 5,000 males. More than 90 per cent of patients become wheelchair-bound by age 15.

Also Read: Affimed puts on hold cancer drug trial after patient death



Source: Reuters
0 comment(s) on U.S. drug developer Capricor places Duchenne drug trial on hold

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted